Study: NCT02573155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1, AZD8871 50 μg (Part 1)
Description: 50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1, AZD8871 50 μg (Part 1)
Description: 50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1, AZD8871 50 μg (Part 1)
Description: 50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2, AZD8871 100 μg (Part 1)
Description: 100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2, AZD8871 100 μg (Part 1)
Description: 100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2, AZD8871 100 μg (Part 1)
Description: 100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 3, AZD8871 300 μg (Part 1)
Description: 300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 3, AZD8871 300 μg (Part 1)
Description: 300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 3, AZD8871 300 μg (Part 1)
Description: 300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 4, AZD8871 600 µg (Part 1)
Description: 600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 4, AZD8871 600 µg (Part 1)
Description: 600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 4, AZD8871 600 µg (Part 1)
Description: 600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 5, AZD8871 1200 µg (Part 1)
Description: 1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 5, AZD8871 1200 µg (Part 1)
Description: 1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 5, AZD8871 1200 µg (Part 1)
Description: 1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 6, AZD8871 1800 μg (Part 1)
Description: 1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 6, AZD8871 1800 μg (Part 1)
Description: 1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 6, AZD8871 1800 μg (Part 1)
Description: 1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, AZD8871 placebo (Part 1)
Description: AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, AZD8871 placebo (Part 1)
Description: AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, AZD8871 placebo (Part 1)
Description: AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, AZD8871 placebo (Part 1)
Description: AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, AZD8871 placebo (Part 1)
Description: AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, AZD8871 placebo (Part 1)
Description: AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A, AZD8871 dose A (Part 2)
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A, AZD8871 dose A (Part 2)
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A, AZD8871 dose A (Part 2)
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A, AZD8871 dose A (Part 2)
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A, AZD8871 dose A (Part 2)
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A, AZD8871 dose A (Part 2)
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A, AZD8871 dose A (Part 2)
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A, AZD8871 dose A (Part 2)
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A, AZD8871 dose A (Part 2)
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A, AZD8871 dose A (Part 2)
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B, AZD8871 dose B (Part 2)
Description: AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B, AZD8871 dose B (Part 2)
Description: AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B, AZD8871 dose B (Part 2)
Description: AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B, AZD8871 dose B (Part 2)
Description: AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B, AZD8871 dose B (Part 2)
Description: AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B, AZD8871 dose B (Part 2)
Description: AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B, AZD8871 dose B (Part 2)
Description: AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B, AZD8871 dose B (Part 2)
Description: AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B, AZD8871 dose B (Part 2)
Description: AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B, AZD8871 dose B (Part 2)
Description: AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C, Indacaterol 150 μg (Part 2)
Description: 150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C, Indacaterol 150 μg (Part 2)
Description: 150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C, Indacaterol 150 μg (Part 2)
Description: 150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C, Indacaterol 150 μg (Part 2)
Description: 150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C, Indacaterol 150 μg (Part 2)
Description: 150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C, Indacaterol 150 μg (Part 2)
Description: 150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C, Indacaterol 150 μg (Part 2)
Description: 150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C, Indacaterol 150 μg (Part 2)
Description: 150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C, Indacaterol 150 μg (Part 2)
Description: 150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C, Indacaterol 150 μg (Part 2)
Description: 150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D, Tiotropium 18 μg (Part 2)
Description: 18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D, Tiotropium 18 μg (Part 2)
Description: 18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D, Tiotropium 18 μg (Part 2)
Description: 18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D, Tiotropium 18 μg (Part 2)
Description: 18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D, Tiotropium 18 μg (Part 2)
Description: 18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D, Tiotropium 18 μg (Part 2)
Description: 18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D, Tiotropium 18 μg (Part 2)
Description: 18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D, Tiotropium 18 μg (Part 2)
Description: 18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D, Tiotropium 18 μg (Part 2)
Description: 18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D, Tiotropium 18 μg (Part 2)
Description: 18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule